Aficamten improves peak oxygen uptake in obstructive HCM

Name: Aficamten improves peak oxygen uptake in obstructive HCM
Uploaded: 2024-07-02T06:00:00+00:00
Description: Aficamten is a novel cardiac myosin inhibitor that targets hypercontractility in patients with obstructive HCM. Its effects were examined in the phase 3 SE

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Hypertrophic Cardiomyopathy
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
- Ahmad Masri, MD, MS
Mavacamten in symptomatic non-obstructive HCM
Mavacamten in symptomatic non-obstructive HCM
ESC Congress 2025
Mavacamten in symptomatic non-obstructive HCM
- Milind Desai, MD
MinuteCE®
Echo essentials for HCM: The heartbeat of diagnosis and treatment
0.52 credits 3 episodes
- Thor Edvardsen, MD, PhD
- Maurizio Pieroni, MD, PhD
- Elena Arbelo, MD, PhD
0.52 credits 3 episodes
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
ACC.24
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
- Martin Maron, MD

Aficamten improves peak oxygen uptake in obstructive HCM

Recommended

Title

Share on ReachMD